SG11201604728XA - Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof - Google Patents

Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Info

Publication number
SG11201604728XA
SG11201604728XA SG11201604728XA SG11201604728XA SG11201604728XA SG 11201604728X A SG11201604728X A SG 11201604728XA SG 11201604728X A SG11201604728X A SG 11201604728XA SG 11201604728X A SG11201604728X A SG 11201604728XA SG 11201604728X A SG11201604728X A SG 11201604728XA
Authority
SG
Singapore
Prior art keywords
immunogenic compositions
capsular saccharide
saccharide antigens
conjugated capsular
conjugated
Prior art date
Application number
SG11201604728XA
Inventor
David Cooper
Emilio Anthony Emini
Jianxin Gu
Mingming Han
Kathrin Ute Jansen
Rajesh Kumar Kainthan
Jin-Hwan Kim
Avvari Krishna Prasad
Michael William Pride
Wendy Jo Watson
Yu-Ying Yang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52630420&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201604728X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of SG11201604728XA publication Critical patent/SG11201604728XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06—Ampoules or carpules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SG11201604728XA 2014-01-21 2015-01-15 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof SG11201604728XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461929547P 2014-01-21 2014-01-21
PCT/IB2015/050315 WO2015110941A2 (en) 2014-01-21 2015-01-15 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Publications (1)

Publication Number Publication Date
SG11201604728XA true SG11201604728XA (en) 2016-08-30

Family

ID=52630420

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201803187VA SG10201803187VA (en) 2014-01-21 2015-01-15 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
SG11201604728XA SG11201604728XA (en) 2014-01-21 2015-01-15 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201803187VA SG10201803187VA (en) 2014-01-21 2015-01-15 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Country Status (28)

Country Link
US (1) US9492559B2 (en)
EP (3) EP3096785B1 (en)
JP (4) JP6335326B2 (en)
KR (4) KR20200108496A (en)
CN (5) CN114887048A (en)
AR (1) AR099445A1 (en)
AU (5) AU2015208821B2 (en)
BR (1) BR112016015525A2 (en)
CA (3) CA3170344C (en)
DK (1) DK3096785T3 (en)
ES (1) ES2820824T3 (en)
FR (2) FR22C1028I1 (en)
HU (3) HUE051728T2 (en)
IL (5) IL296681B1 (en)
MX (4) MX2016009470A (en)
NO (2) NO2022021I1 (en)
NZ (5) NZ760783A (en)
PE (2) PE20161095A1 (en)
PH (2) PH12016501243A1 (en)
PL (1) PL3096785T3 (en)
PT (1) PT3096785T (en)
RU (1) RU2771293C2 (en)
SA (1) SA516371506B1 (en)
SG (2) SG10201803187VA (en)
SI (1) SI3096785T1 (en)
TW (4) TWI679987B (en)
WO (1) WO2015110941A2 (en)
ZA (1) ZA201603925B (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824997B1 (en) 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
ES2382048T3 (en) 2005-04-08 2012-06-04 Wyeth Llc Multivalent pneumococcal protein-polysaccharide conjugate composition
US9517274B2 (en) 2012-08-16 2016-12-13 Pfizer Inc. Glycoconjugation processes and compositions
AU2015208820B2 (en) * 2014-01-21 2020-05-14 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20210032013A (en) * 2014-01-21 2021-03-23 화이자 인코포레이티드 Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
NZ760783A (en) 2014-01-21 2023-07-28 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL252915B2 (en) 2015-01-15 2024-04-01 Pfizer Immunogenic compositions for use in pneumococcal vaccines
JP6882193B2 (en) * 2015-04-28 2021-06-02 バイオロジカル イー リミテッド Methods for Separating Proteins and Other Impurities from Microbacterial Capsular Polysaccharides
AU2016258284C1 (en) * 2015-05-04 2020-09-03 Pfizer Inc. Group B Streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
AU2016295566B2 (en) * 2015-07-21 2019-06-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
EP3377098A1 (en) * 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
CN106110316A (en) * 2016-06-27 2016-11-16 北京智飞绿竹生物制药有限公司 A kind of preparation method of streptococcus pneumoniae conjugate combination-vaccine
JP7001686B2 (en) * 2016-08-05 2022-02-04 サノフィ パスツール インコーポレイティッド Polyvalent pneumococcal polysaccharide-protein conjugate composition
TWI789357B (en) * 2016-08-05 2023-01-11 南韓商Ｓｋ生物科技股份有限公司 Multivalent pneumococcal polysaccharide-protein conjugate composition
AR109621A1 (en) * 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc FORMULATIONS OF VACCINES AGAINST GLUCOCONJUGADOS OF EXPEC
CN108144052A (en) * 2016-12-02 2018-06-12 武汉博沃生物科技有限公司 Streptococcus pneumoniae polysaccharides-protein conjugate and its preparation method and purposes
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
WO2018126229A2 (en) 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
BR112019014833A2 (en) * 2017-01-20 2020-04-14 Pfizer immunogenic compositions for use in pneumococcal vaccines
CN116870144A (en) * 2017-01-31 2023-10-13 默沙东有限责任公司 Method for preparing polysaccharide-protein conjugates
EP3576759A4 (en) 2017-01-31 2020-11-11 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
CA3052621A1 (en) 2017-02-03 2018-08-09 Schadeck, Eva Barbara Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
CN110337307A (en) * 2017-02-24 2019-10-15 默沙东公司 Enhance streptococcus pneumoniae polysaccharides-protein conjugate immunogenicity
BR112019017390A2 (en) * 2017-02-24 2020-03-31 Merck Sharp & Dohme Corp. PNEUMOCOCCAL CONJUGATED VACCINE FORMULATIONS AND USE OF THE SAME
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CA3066911C (en) 2017-06-10 2022-05-24 Inventprise, Llc Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
AU2018318074A1 (en) * 2017-08-14 2020-02-27 University Of Georgia Research Foundation, Inc. Proteins having pneumococcal capsule degrading activity and methods of use
US20200360500A1 (en) * 2017-08-16 2020-11-19 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
US11491216B2 (en) * 2017-09-07 2022-11-08 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CN111065387B (en) 2017-09-07 2023-08-25 默沙东有限责任公司 Pneumococcal polysaccharide and its use in immunogenic polysaccharide-carrier protein conjugates
CN111093650B (en) * 2017-09-07 2024-03-01 默沙东有限责任公司 Pneumococcal polysaccharide and its use in immunogenic polysaccharide-carrier protein conjugates
BR112020004471A8 (en) 2017-09-07 2022-11-01 Merck Sharp & Dohme PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES
NZ765694A (en) * 2017-12-06 2024-03-22 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CA3087572A1 (en) 2018-02-05 2019-08-08 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
JP6950099B2 (en) * 2018-02-05 2021-10-13 サノフィ パスツール インコーポレイティッド Polyvalent pneumococcal polysaccharide-protein complex composition
JP2021522213A (en) * 2018-04-18 2021-08-30 エスケー バイオサイエンス カンパニー リミテッド Streptococcus pneumoniae capsular polysaccharide and its immunogenic zygotes
CN112074293A (en) * 2018-04-30 2020-12-11 默沙东公司 Method for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
US11896656B2 (en) 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
CN112074294A (en) * 2018-04-30 2020-12-11 默沙东公司 Method for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugate from freeze-dried spheres
MX2020014118A (en) * 2018-07-04 2021-06-18 Vaxcyte Inc Improvements in immunogenic conjugates.
WO2020009462A1 (en) * 2018-07-06 2020-01-09 주식회사 유바이오로직스 Multivalent immunogenic composition comprising polysaccharide-protein conjugates, and vaccine comprising same for preventing disease caused by streptococcus pneumoniae
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
US11103567B2 (en) * 2018-12-06 2021-08-31 Academia Sinica Glycoconjugate vaccines, preparation method and uses thereof
US20220016229A1 (en) 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
US20220296695A1 (en) 2018-12-19 2022-09-22 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2020152706A1 (en) * 2019-01-21 2020-07-30 Biological E Limited Multivalent pneumococcal conjugate vaccine compositions
WO2020157772A1 (en) * 2019-01-28 2020-08-06 Biological E Limited Multivalent pneumococcal polysaccharide-protein conjugate vaccine compositions
JP7239509B6 (en) * 2019-02-22 2023-03-28 ファイザー・インク Method for purifying bacterial polysaccharides
EP4003410A1 (en) * 2019-07-31 2022-06-01 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
US20230085173A1 (en) 2020-02-21 2023-03-16 Pfizer Inc. Purification of saccharides
EP4232593A1 (en) 2020-10-22 2023-08-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
JP2023549736A (en) 2020-11-10 2023-11-29 ファイザー・インク Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202306969A (en) 2021-05-28 2023-02-16 美商輝瑞大藥廠 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN115721709A (en) * 2021-08-27 2023-03-03 康希诺生物股份公司 Preparation method of pneumococcal conjugate vaccine
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4686102A (en) * 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE
DE68907045T2 (en) 1989-01-17 1993-12-02 Eniricerche Spa Synthetic peptides and their use as general carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines.
CA2063271A1 (en) 1989-07-14 1991-01-15 Subramonia Pillai Cytokine and hormone carriers for conjugate vaccines
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE
DE69113564T2 (en) 1990-08-13 1996-05-30 American Cyanamid Co Bordetella pertussis fiber hemagglutinin as a carrier for conjugated vaccine.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
EP0911036A3 (en) 1992-02-11 2001-05-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
IT1262896B (en) 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
CA2135052A1 (en) 1992-05-06 1993-11-11 R. John Collier Diphtheria toxin receptor-binding region
SG90042A1 (en) 1992-06-25 2002-07-23 Smithkline Beecham Biolog Vaccine composition containing adjuvants
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
PT616034E (en) 1993-03-05 2005-02-28 Wyeth Corp PLASMIDEO FOR THE PRODUCTION OF PROTEIN CRM AND DIPHTHERIA TOXIN
WO1994021292A1 (en) 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
CA2171942C (en) 1993-09-22 2010-12-14 Andrew Lees Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
JP3468773B2 (en) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション Immunomodulatory oligonucleotide
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
NZ304715A (en) 1995-03-22 1999-07-29 Jackson H M Found Military Med Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten
US5714354A (en) * 1995-06-06 1998-02-03 American Home Products Corporation Alcohol-free pneumococcal polysaccharide purification process
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
WO1998052581A1 (en) 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
EP1067956B1 (en) 1998-04-03 2007-03-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
BR9909915A (en) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
WO2000023105A2 (en) 1998-10-16 2000-04-27 Smithkline Beecham Biologicals S.A. Adjuvant systems and vaccines
EP1140157B1 (en) 1998-12-21 2009-02-18 MedImmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
CN1191362C (en) 1998-12-23 2005-03-02 夏尔生化公司 Streptococcus antigens
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
CA2362204C (en) 1999-02-17 2011-11-08 John Cooper Cox Immunogenic complexes and methods relating thereto
EP1034792A1 (en) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
EP1880735A3 (en) 1999-03-19 2008-03-12 GlaxoSmithKline Biologicals S.A. Vaccine
JP2002541808A (en) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Recombinant toxin A protein carrier for polysaccharide conjugate vaccine
AU764969B2 (en) 1999-04-19 2003-09-04 Smithkline Beecham Biologicals (Sa) Vaccines
KR20020048942A (en) 1999-09-24 2002-06-24 장 스테판느 Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one nonionic surfactant
MXPA02003067A (en) 1999-09-24 2002-09-30 Smithkline Beecham Biolog Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines.
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
WO2001098334A2 (en) 2000-06-20 2001-12-27 Shire Biochem Inc. Streptococcus antigens
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
JP4360906B2 (en) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー In vivo activation of antigen-presenting cells to enhance the immune response induced by virus-like particles
WO2003054007A2 (en) 2001-12-20 2003-07-03 Shire Biochem Inc. Streptococcus antigens
MXPA05009579A (en) 2003-03-13 2005-11-17 Glaxosmithkline Biolog Sa Purification process for bacterial cytolysin.
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
WO2007026190A2 (en) 2004-07-18 2007-03-08 Csl Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
CA2604362C (en) 2005-04-08 2013-11-12 Wyeth Separation of contaminants from streptococcus pneumoniae polysaccharide by ph manipulation
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
ES2382048T3 (en) * 2005-04-08 2012-06-04 Wyeth Llc Multivalent pneumococcal protein-polysaccharide conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
DK2283857T3 (en) 2005-06-27 2019-10-28 Glaxosmithkline Biologicals Sa Vaccine composition comprising conjugated native N. Meningitidis capsule polysaccharides
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
TWI465248B (en) * 2005-12-22 2014-12-21 Glaxosmithkline Biolog Sa Streptococcus pneumoniae immunogenic composition comprising capsular saccharide conjugates, vaccine and kit comprising the same and uses thereof
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
RU2460539C2 (en) 2006-10-10 2012-09-10 Вайет METHOD FOR TYPE 3 Streptococcus pneumoniae POLYSACCHARIDE PURIFICATION (VERSIONS)
HUE031567T2 (en) 2007-03-23 2017-07-28 Wyeth Llc Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
ES2621359T3 (en) * 2007-06-20 2017-07-03 Pfizer Ireland Pharmaceuticals Modified polysaccharides for conjugate vaccines
EA200901578A1 (en) * 2007-06-26 2010-08-30 Глаксосмитклайн Байолоджикалс С.А. VACCINE CONTAINING CONJUGATES OF CAPSULAR POLYSACCHARIDES STREPTOCOCCUS PNEUMONIAE
CA2756398A1 (en) * 2009-03-24 2010-09-30 Novartis Ag Combinations including pneumococcal serotype 14 saccharide
KR101450958B1 (en) * 2009-04-30 2014-10-15 콜레이 파마시티컬 그룹, 인코포레이티드 Pneumococcal vaccine and uses therof
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
WO2011145108A2 (en) * 2010-05-15 2011-11-24 Serum Institute Of India Ltd. Purification of capsular polysaccharides
CN103391714A (en) * 2010-12-10 2013-11-13 默沙东公司 Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
US9517274B2 (en) * 2012-08-16 2016-12-13 Pfizer Inc. Glycoconjugation processes and compositions
PT3363806T (en) 2012-12-20 2022-12-16 Pfizer Glycoconjugation process
ITMI20130142A1 (en) * 2013-01-31 2014-08-01 Biosynth Srl GLYCOCOUGUGAR VACCINES INCLUDING BASIC UNITS OF AN EXPRIMENT MOLECULAR CONSTRUCTED MULTIPLE EPITHOPES INCORPORATED
CN103495161B (en) 2013-10-08 2019-06-18 江苏康泰生物医学技术有限公司 A kind of mixture and preparation method thereof of polynary pneumococcal capsular polysaccharide-protein conjugate
NZ760783A (en) 2014-01-21 2023-07-28 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Also Published As

Publication number Publication date
NZ759686A (en) 2023-07-28
EP3616716A2 (en) 2020-03-04
WO2015110941A2 (en) 2015-07-30
SI3096785T1 (en) 2020-12-31
JP6335326B2 (en) 2018-05-30
PH12016501243B1 (en) 2016-08-15
NO2022021I1 (en) 2022-06-09
AU2021206895B2 (en) 2024-02-22
AU2015208821A1 (en) 2016-07-07
US20150202309A1 (en) 2015-07-23
TWI715285B (en) 2021-01-01
NO2022035I1 (en) 2022-08-04
JP7059095B2 (en) 2022-04-25
MX2016009470A (en) 2017-01-18
ZA201603925B (en) 2017-09-27
EP3607966A1 (en) 2020-02-12
CN106102770A (en) 2016-11-09
IL296681B1 (en) 2024-05-01
JP2018135374A (en) 2018-08-30
FR22C1040I1 (en) 2022-09-09
ES2820824T3 (en) 2021-04-22
AU2017268651B2 (en) 2019-08-01
IL283058A (en) 2021-06-30
CA3170344C (en) 2023-08-29
PH12021550318A1 (en) 2021-10-04
NZ760783A (en) 2023-07-28
SA516371506B1 (en) 2021-06-01
MX2021000522A (en) 2021-06-08
PE20212335A1 (en) 2021-12-16
AU2021206895A1 (en) 2021-08-12
AU2024201996A1 (en) 2024-05-16
JP7227943B2 (en) 2023-02-22
TW201531299A (en) 2015-08-16
KR20160098507A (en) 2016-08-18
EP3096785B1 (en) 2020-09-09
IL283058B (en) 2022-10-01
KR20220080201A (en) 2022-06-14
AU2019204623B2 (en) 2021-04-29
IL283058B2 (en) 2023-02-01
PE20161095A1 (en) 2016-10-26
US9492559B2 (en) 2016-11-15
CN114848805A (en) 2022-08-05
RU2016129991A (en) 2018-03-01
CN114887048A (en) 2022-08-12
BR112016015525A2 (en) 2017-10-24
SG10201803187VA (en) 2018-05-30
NZ755770A (en) 2023-06-30
HUS2200035I1 (en) 2022-08-28
AR099445A1 (en) 2016-07-27
CA3170344A1 (en) 2015-07-30
AU2019204623A1 (en) 2019-07-18
KR20200108496A (en) 2020-09-18
TWI682778B (en) 2020-01-21
IL282215B (en) 2022-10-01
IL246853B (en) 2021-04-29
EP3616716A3 (en) 2020-05-06
JP2017509656A (en) 2017-04-06
RU2019112411A3 (en) 2021-06-24
KR102157200B1 (en) 2020-09-21
MX2021000520A (en) 2021-06-08
AU2017268651A1 (en) 2017-12-21
CA2937186A1 (en) 2015-07-30
IL296681A (en) 2022-11-01
MX2021000523A (en) 2021-06-23
IL282215B2 (en) 2023-02-01
RU2771293C2 (en) 2022-04-29
PL3096785T3 (en) 2021-03-08
RU2687460C2 (en) 2019-05-13
HUE051728T2 (en) 2021-03-29
CA3206112A1 (en) 2015-07-30
TWI748810B (en) 2021-12-01
IL246853A0 (en) 2016-08-31
PT3096785T (en) 2020-10-13
NZ755769A (en) 2023-06-30
AU2015208821B2 (en) 2017-11-02
RU2016129991A3 (en) 2018-03-01
JP2023065429A (en) 2023-05-12
FR22C1028I1 (en) 2022-09-09
IL282215A (en) 2021-05-31
CA2937186C (en) 2022-11-01
TW202003024A (en) 2020-01-16
JP2020164550A (en) 2020-10-08
CN110859957B (en) 2024-04-12
WO2015110941A3 (en) 2015-11-26
IL270090B (en) 2021-05-31
TW201828978A (en) 2018-08-16
EP3096785A2 (en) 2016-11-30
KR20230021167A (en) 2023-02-13
CN110859957A (en) 2020-03-06
CN110787290A (en) 2020-02-14
TWI679987B (en) 2019-12-21
DK3096785T3 (en) 2020-09-21
CN106102770B (en) 2022-03-22
RU2019112411A (en) 2019-05-31
PH12016501243A1 (en) 2016-08-15
HUS2200029I1 (en) 2022-07-28
NZ721943A (en) 2022-07-01
TW202112392A (en) 2021-04-01

Similar Documents

Publication Publication Date Title
HUS2200035I1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
ZA201903620B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
IL248239A0 (en) Anti - her3 antibody - drug conjugates, compositions comprising same and uses thereof
IL254016A0 (en) Therapeutic and prophylactic composition produced by microbiota
EP3142695A4 (en) Compositions and methods of enhancing immunogenicity of polysaccharide-protein conjugates
IL251120B (en) Immunogenic/therapeutic glycoconjugate compositions and uses thereof
ZA201608487B (en) Dual adjuvant vaccine compositions, preparation and uses
GB201610599D0 (en) Immunogenic Composition
PT3223796T (en) Pharmaceutical compositions, preparation and uses thereof
ZA201608327B (en) Curcumin-peptide conjugates and formulations thereof
GB201721582D0 (en) S aureus antigens and immunogenic compositions
GB201614485D0 (en) Immunogenic composition
IL271603A (en) Immunogenic compositions
GB201604755D0 (en) Immunogenic compositions
GB201911959D0 (en) Immunogenic compositions and uses therefor
SG11202004167XA (en) Immunogenic compositions and uses therefor
GB201712096D0 (en) Immunogenic conjugates and use thereof
AU2014902031A0 (en) Immunogenic vaccines and uses thereof